Just 1 mill of them get the test each year....rebate around US $360 (from memory), so a test cost of around $600 AUD. And that's $600 mill revenue. I think 70% margin is not too high...$420 mill GPM. And like bowel cancer screening, it will probably be repeated every 3-4 years as a precaution.
Thats just the D test. Every suspected case of esophogial cancer would consider a blood test before more invasive and expensive tests. Endometriosis is absolutely massive, and crying out for such a test. I can't even imagine how big the muscle damage test will be considering the emphasis on protecting professional athletes, and horses.
The market short term is not going to be kind, except as an opportunity to buy before revenue starts to roll in. No better potential biotech in the market medium to long term IMO.
Milesy
PIQ Price at posting:
48.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)